bluebird bio, a clinical-stage biotech focused on treating severe genetic and orphan diseases with gene therapy, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, bluebird bio would command a market value of $328 million.
The Cambridge, MA-based company, which was founded in 1992 and booked $1 million in collaboration revenue in the first quarter of 2013, plans to list on the NASDAQ under the symbol BLUE. bluebird bio initially filed confidentially on March 21, 2013. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal.